In April 2019, Finland reported false-negative or equivocal results in patients tested for Chlamydia trachomatis (CT) using Aptima Combo 2 Assay (Hologic) (AC2).
ECDC and EFSA have assessed the risk to the EU/EEA posed by a fatal human case of Bacillus anthracis infection in Bulgaria and concluded that this event represents a negligible risk to other EU/EEA countries.
New and noteworthy in this update: the retrospective identification of novel coronavirus in biological samples from two fatal cases in Jordan (April 2012) and the results of a joint ECDC/WHO survey which confirms that EU/EEA Member States have an adequate capacity to detect novel coronavirus through their network of national reference laboratories: 18 of 30 in EU/EEA countries are capable of confirming positive screened samples by either ORF1b RT-PCR or other target RT-PCR assays with sequence analysis or whole-genome sequence analysis.
CDC updated risk assessment concludes that in the absence of evidence of sustained person-to-person transmission outside of household settings, the current facts still point towards a hypothesis of a zoonotic or environmental source with occasional transmission to exposed humans. WHO does not advise any travel or trade restrictions at this point for KSA or Qatar.
The US CDC reported an outbreak of Hantavirus Pulmonary Syndrome (HPS) associated with staying in the ’Signature Tent Cabins’ in the Boystown area of Curry Village at Yosemite National Park, California, USA.
This is an update to the joint rapid risk assessment published on 6 July 2012 by ECDC and EMCDDA on anthrax cases among injecting drug users in Germany. This is in response to further cases in France and Denmark. It contains information updated up to the 13 July 2012.
This is an update to the joint rapid risk assessment published on 22 June 2012 by ECDC and EMCDDA on anthrax cases among injecting drug users in Germany. This is in response to a third case in Berlin. It contains information updated up to the 6 July 2012.